CY1111599T1 - Αναστολεις κινασης θειενοπυριδινης και φουροπυριδινης - Google Patents

Αναστολεις κινασης θειενοπυριδινης και φουροπυριδινης

Info

Publication number
CY1111599T1
CY1111599T1 CY20091100278T CY091100278T CY1111599T1 CY 1111599 T1 CY1111599 T1 CY 1111599T1 CY 20091100278 T CY20091100278 T CY 20091100278T CY 091100278 T CY091100278 T CY 091100278T CY 1111599 T1 CY1111599 T1 CY 1111599T1
Authority
CY
Cyprus
Prior art keywords
fouropyridine
thienopyridine
compounds
kinase inhibitions
inhibitions
Prior art date
Application number
CY20091100278T
Other languages
English (en)
Inventor
Patrick Betschmann
Andrew F Burchat
David J Calderwood
Michael L Curtin
Steven K Davidsen
Heather M Davis
Robin R Frey
Howard R Heyman
Gavin C Hirst
Peter Hrnciar
Michael R Michaelides
Melanie A Muckey
Paul Rafferty
Carol K Wada
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/626,092 external-priority patent/US20050020619A1/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CY1111599T1 publication Critical patent/CY1111599T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

Ενώσεις που έχουν τον χημικό τύπο: (I), είναι χρήσιμες για την αναστολή κινασών τυροσίνης πρωτεΐνης. Στην παρούσα εφεύρεση αποκαλύπτονται και δημοσιοποιούνται ως αναφορά επίσης μέθοδοι για την παρασκευή των ενώσεων, των συνθέσεων που περιέχουν τις ενώσεις, και των μεθόδων αγωγής χρησιμοποιώντας τις ενώσεις.
CY20091100278T 2003-07-24 2009-03-12 Αναστολεις κινασης θειενοπυριδινης και φουροπυριδινης CY1111599T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/626,092 US20050020619A1 (en) 2003-07-24 2003-07-24 Thienopyridine kinase inhibitors
US10/838,132 US20050026944A1 (en) 2003-07-24 2004-05-03 Thienopyridine and furopyridine kinase inhibitors
EP04779180A EP1648905B1 (en) 2003-07-24 2004-07-26 Thienopyridine and furopyridine kinase inhibitors

Publications (1)

Publication Number Publication Date
CY1111599T1 true CY1111599T1 (el) 2015-10-07

Family

ID=34108157

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100278T CY1111599T1 (el) 2003-07-24 2009-03-12 Αναστολεις κινασης θειενοπυριδινης και φουροπυριδινης

Country Status (19)

Country Link
US (1) US20050026944A1 (el)
EP (1) EP1648905B1 (el)
JP (1) JP4707192B2 (el)
KR (2) KR20110123797A (el)
CN (1) CN103087078A (el)
AT (1) ATE419253T1 (el)
AU (2) AU2004259765B2 (el)
BR (1) BRPI0412894A (el)
CA (1) CA2532982C (el)
CY (1) CY1111599T1 (el)
DE (1) DE602004018780D1 (el)
DK (1) DK1648905T3 (el)
ES (1) ES2319302T3 (el)
IL (1) IL173348A (el)
MX (1) MXPA06000919A (el)
NZ (1) NZ544712A (el)
PL (1) PL1648905T3 (el)
PT (1) PT1648905E (el)
WO (1) WO2005010009A1 (el)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528685A (ja) * 2003-05-06 2006-12-21 スミスクライン ビーチャム コーポレーション 新規化合物
US7899855B2 (en) * 2003-09-08 2011-03-01 Intel Corporation Method, apparatus and instructions for parallel data conversions
GB0325836D0 (en) * 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US20050256154A1 (en) * 2004-05-04 2005-11-17 Kin-Chun Luk 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides
US20060281768A1 (en) * 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
US7566721B2 (en) * 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
BRPI0520482A2 (pt) * 2005-08-16 2009-05-12 Hoffmann La Roche amidas do ácido 4-amino-tieno [3,2-c] piridina-7-carboxìlico
KR100968099B1 (ko) * 2005-09-15 2010-07-06 에프. 호프만-라 로슈 아게 4-아미노-티에노[3,2-ｃ]피리딘-7-카르복실산 유도체
WO2007056625A2 (en) * 2005-11-04 2007-05-18 Smithkline Beecham Corporation Thienopyridine b-raf kinase inhibitors
CA2631664C (en) * 2005-12-08 2012-05-08 Abbott Laboratories 9-membered heterobicyclic compounds as inhibitors of protein kinases
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
JP5512975B2 (ja) 2005-12-29 2014-06-04 アッヴィ・インコーポレイテッド タンパク質キナーゼ阻害薬
US7659283B2 (en) * 2006-02-14 2010-02-09 Vertex Pharmaceuticals Incorporated Pyrrolo [3,2-C] pyridines useful as inhibitors of protein kinases
US7932390B2 (en) * 2006-06-29 2011-04-26 Hoffman-La Roche Inc. Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
US7994321B2 (en) * 2006-08-08 2011-08-09 Hoffmann-La Roche Inc. Substituted thieno[3,2-C]pyridine-7-carboxylic acid derivatives
WO2008018881A1 (en) * 2006-08-10 2008-02-14 Osi Pharmaceuticals, Inc. 6,6-bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors
MX2010001636A (es) * 2007-08-14 2010-03-15 Hoffmann La Roche Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
CA2723358A1 (en) * 2008-05-05 2009-11-12 Allison B. Reiss Method for improving cardiovascular risk profile of cox inhibitors
CA2743592A1 (en) * 2008-12-05 2010-06-10 Abbott Laboratories Thienopyridine kinase inhibitors with improved cyp safety profile
CN102574843B (zh) 2009-10-22 2015-06-17 法博太科制药有限公司 抗纤维化剂的稠环类似物
TWI482770B (zh) * 2010-06-09 2015-05-01 Abbvie Bahamas Ltd 結晶型激酶抑制劑
TWI492949B (zh) * 2010-06-09 2015-07-21 Abbvie Bahamas Ltd 結晶型激酶抑制劑
WO2011156473A1 (en) * 2010-06-09 2011-12-15 Abbott Laboratories Crystalline forms of kinase inhibitors
EP2588098A1 (en) 2010-07-02 2013-05-08 Alcon Research, Ltd. Compounds for the treatment of posterior segment disorders and diseases
RU2013120966A (ru) * 2010-10-08 2014-11-20 Эббви Инк. ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ
US8436179B2 (en) 2011-07-20 2013-05-07 Abbvie Inc. Kinase inhibitor with improved solubility profile
CN103396414B (zh) * 2013-07-16 2015-06-03 浙江医药高等专科学校 咪唑取代的噻唑并环己烷类化合物、及其抗肿瘤用途
CN104945411B (zh) * 2014-03-27 2018-07-31 南京勇山生物科技有限公司 噻吩并[3,2-c]吡啶类化合物、其制备方法及应用
WO2015157360A1 (en) 2014-04-08 2015-10-15 Abbvie Inc. Processes to make protein kinase inhibitors
WO2016047678A1 (ja) * 2014-09-25 2016-03-31 武田薬品工業株式会社 複素環化合物
MX2019009235A (es) 2017-02-03 2019-12-11 Certa Therapeutics Pty Ltd Compuestos antifibroticos.
US11912668B2 (en) 2020-11-18 2024-02-27 Deciphera Pharmaceuticals, Llc GCN2 and perk kinase inhibitors and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ503685A (en) * 1997-10-20 2002-05-31 F Fused pyrrole compounds as kinase inhibitors
CA2348740A1 (en) * 1998-12-23 2000-07-06 Ruth R. Wexler Thrombin or factor xa inhibitors
PL354241A1 (en) * 1999-09-17 2003-12-29 Abbott Gmbh & Co.Kgabbott Gmbh & Co.Kg Kinase inhibitors as therapeutic agents
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
DE60144322D1 (de) * 2000-04-27 2011-05-12 Astellas Pharma Inc Kondensierte heteroarylderivate
EP1373240B1 (en) * 2001-03-14 2005-06-15 Eli Lilly And Company Retinoid x receptor modulators
AU2002333524A1 (en) * 2001-09-11 2003-03-24 Glaxosmithkline K.K. Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
JP2006528685A (ja) * 2003-05-06 2006-12-21 スミスクライン ビーチャム コーポレーション 新規化合物

Also Published As

Publication number Publication date
CN103087078A (zh) 2013-05-08
DE602004018780D1 (de) 2009-02-12
CA2532982A1 (en) 2005-02-03
AU2004259765B2 (en) 2009-10-22
CA2532982C (en) 2013-11-26
IL173348A0 (en) 2006-06-11
EP1648905B1 (en) 2008-12-31
WO2005010009A1 (en) 2005-02-03
KR101120936B1 (ko) 2012-03-29
KR20060056344A (ko) 2006-05-24
AU2004259765A1 (en) 2005-02-03
NZ544712A (en) 2009-09-25
EP1648905A1 (en) 2006-04-26
ATE419253T1 (de) 2009-01-15
JP2006528646A (ja) 2006-12-21
US20050026944A1 (en) 2005-02-03
PT1648905E (pt) 2009-04-08
BRPI0412894A (pt) 2006-10-03
AU2009251083B2 (en) 2012-02-16
MXPA06000919A (es) 2006-05-04
DK1648905T3 (da) 2009-03-30
AU2009251083A1 (en) 2010-01-21
IL173348A (en) 2015-11-30
KR20110123797A (ko) 2011-11-15
JP4707192B2 (ja) 2011-06-22
ES2319302T3 (es) 2009-05-06
PL1648905T3 (pl) 2009-07-31

Similar Documents

Publication Publication Date Title
CY1111599T1 (el) Αναστολεις κινασης θειενοπυριδινης και φουροπυριδινης
ATE554087T1 (de) Neue kinaseinhibitoren
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
DK1638941T3 (da) Indazol-, benzisoxazol- og benzisothiazolkinaseinhibitorer
PT1347971E (pt) Inibidores tiazolilicos de tirosina-cinases da familia tec
CY1109681T1 (el) Υποκατεστημενα παραγωγα κιναζολινης ως αναστολεις των κινασων aurora
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
BRPI0508220A (pt) derivados de pirazol heteroarila fundidos
CY1110914T1 (el) Δικυκλο-πυραζολες δραστικες ως αναστολεις kinασων, διεργασια για την παρασκευη τους και φαρμακευτικες συνθεσεις που τις περιλαμβανουν
CY1110225T1 (el) Κυκλικοι αναστολεις πρωτεϊνικης τυροσινικης κινασης
PL406680A1 (pl) Inhibitory kinaz tyrozynowych
IL173916A0 (en) Thienopyrazoles
MXPA06010904A (es) Inhibidores de pirazol cinasa triciclicos.
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
BRPI0407841A (pt) inibidores heterocìclicos de quinase
BR0308606A (pt) Derivados de hemiasterlina e usos destes
DK1606288T3 (da) Benzensulfonamidderivater, fremgangsmåde til fremstilling deraf og deres anvendelse til behandling af smerte
MXPA04005809A (es) Inhibidores de proteinas quinasas.
SE0100374D0 (sv) Novel compositions of potassium channel openers and protein kinase c inhibitors and use thereof
ATE540951T1 (de) Substituierte 7,8-dihydro-1h-pyrimidoä4,5- büdiazepin-4-amine als kinase inhibitoren